NCT03278899 is a clinical trial in X-Linked Adrenoleukodystrophy, sponsored by NeuroVia, Inc..

Who is sponsoring NCT03278899?

NCT03278899 is sponsored by NeuroVia, Inc..

What condition does NCT03278899 study?

NCT03278899 studies X-Linked Adrenoleukodystrophy.

Is NCT03278899 still recruiting?

NCT03278899 is currently status unknown. Last updated 8 August 2018.

Last reviewed 2018-08-08 · How we verify

NCT03278899

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study to Prospectively Assess Disease Progression in Male Children With X-ALD

Status unknown Last updated 8 August 2018

What this trial tests

trial in X-Linked Adrenoleukodystrophy in 100 participants. Status unknown.

Timeline

16 February 2018

Primary endpoint
1 June 2021

1 June 2021

Quick facts

Lead sponsor	NeuroVia, Inc.
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	100
Start date	16 February 2018
Primary completion	1 June 2021
Estimated completion	1 June 2021
Sites	3 locations across United States

Conditions studied

X-Linked Adrenoleukodystrophy — all drugs for X-Linked Adrenoleukodystrophy →

Sponsor

NeuroVia, Inc. — full company profile →

Who can join

Adults 2 to 13, male only, with X-Linked Adrenoleukodystrophy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a non-interventional, multi-center study that follows general principles of periodic assessment of X-ALD patients in routine practice. No study drug treatment will be given and no changes to patient treatment are necessary.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03278899 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by NeuroVia, Inc.
Last refreshed: 8 August 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03278899.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing